Ten years of tiotropium: clinical impact and patient perspectives

References

• World Health OrganizationCOPD predicted to be third leading cause of death in 2030 [webpage on the Internet]GenevaWorld Health Organization2008 Available from: http://www.who.int/respiratory/copd/World_Health_Statistics_2008/en/index.htmlAccessed February 12, 2013
   Google Scholar
• MathersCDLoncarDProjections of global mortality and burden of disease from 2002 to 2030PLoS Med2007311e44217132052
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human ServicesNational Institutes of HealthNational Heart Lung and Blood InstituteMorbidity and Mortality: 2009 Chart book on Cardiovascular, Lung and Blood Diseases. [webpage on the Internet] Available from: http://www.nhlbi.nih.gov/about/factbook-09/chapter4.htmAccessed February 12, 2013
   Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management, and prevention of COPD [webpage on the Internet]Vancouver, WAGlobal Initiative for Chronic Obstructive Lung Disease2011 [updated Dec 2011]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013.pdfAccessed February 12, 2013
   Google Scholar
• National Institute for Health and Clinical ExcellenceChronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary CareLondonNational Clinical Guideline Centre2010 Available from: http://guidance.nice.org.uk/CG101/Guidance/pdf/EnglishAccessed February 12, 2013
   Google Scholar
• VogelmeierCHedererBGlaabTPOET-COPD InvestigatorsTiotropium versus salmeterol for the prevention of exacerbations of COPDN Engl J Med2011364121093110321428765
   PubMed Web of Science ®Google Scholar
• CalverleyPMAndersonJACelliBTORCH investigatorsSalmeterol and flucticasone propionate and survival in chronic obstructive pulmonary diseaseN Engl J Med2007356877578917314337
   PubMed Web of Science ®Google Scholar
• TashkinDPCelliBSennSUPLIFT Study InvestigatorsA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• WedzichaJACalverleyPMSeemungalTAHaganGAnsariZStockleyRAINSPIRE InvestigatorsThe prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromideAm J Respir Crit Care Med20081771192617916806
   PubMed Web of Science ®Google Scholar
• AaronSDVandehmheenKLFergussonDCanadian Thoracic Society/Canadian Respiratory Clinical Research ConsortiumTiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2007146854555517310045
   PubMed Web of Science ®Google Scholar
• BourbeauJBartlettSJPatient adherence in COPDThorax200863983183818728206
   PubMed Web of Science ®Google Scholar
• Boehringer Ingelheim GmbHAnnual Report 2011IngelheimBoehringer Ingelheim GmbH2011 Available from: http://www.boehringer-ingelheim.com/content/dam/internet/opu/com_EN/document/01_news/08_APC/APC_2012/BoehringerIngelheim_Annual_Report_2011_complete.pdfAccessed November 8, 2012
   Google Scholar
• BarrRGBourbeauJCamargoCARamFSTiotropium for stable chronic obstructive pulmonary disease: a meta-analysisThorax2006611085486216844726
   PubMed Web of Science ®Google Scholar
• KestenSJaraMWentworthCLanesSPooled clinical trials analysis of tiotropium safetyChest200613061695170317166984
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDInhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysisJAMA2008300121439145018812535
   PubMed Web of Science ®Google Scholar
• CelliBDecramerMLeimerIVogelUKestenSTashkinDPCardiovascular safety of tiotropium in patients with COPDChest20101371203019592475
   PubMed Web of Science ®Google Scholar
• HalpinDMenjogeSVielKPatient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisationsPrim Care Respir J200918210611319407916
   PubMedGoogle Scholar
• YohannesAMWillgossTGVestboJTiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomesRespir Care201156447748721255503
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKEnrightPLFurbergCDMortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trialsBMJ2011342d321521672999
   PubMed Web of Science ®Google Scholar
• DongYHLinHHShauWYWuYCChangCHLaiMSComparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trialsThorax2013681485623042705
   PubMed Web of Science ®Google Scholar
• KarnerCChongJPoolePTiotropium versus placebo for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20127CD00928522786525
   PubMed Web of Science ®Google Scholar
• ChongJKarnerCPoolePTiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary diseaseCochrane Database Syst Rev20129CD00915722972134
   PubMed Web of Science ®Google Scholar
• BarnesPJThe role of anticholinergics in chronic obstructive pulmonary diseaseAm J Med2004117Suppl 12A24S32S15693640
   PubMed Web of Science ®Google Scholar
• BatermanEDRennardSBarnesPJAlternative mechanisms for tiotropiumPulm Pharmacol Ther200922653354219635581
   PubMed Web of Science ®Google Scholar
• NovelliFMalagrinòLDenteFLPaggiaroPEfficacy of anti-cholinergic drugs in asthmaExpert Rev Respir Med20126330931922788945
   PubMed Web of Science ®Google Scholar
• BelmonteKECholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary diseaseProc Am Thorac Soc20052429730416267352
   PubMedGoogle Scholar
• GosensRZaggsmaJMeursHHalaykoJMuscarine receptor signaling in the pathophysiology of asthma and COPDRespir Res200677316684353
   PubMed Web of Science ®Google Scholar
• AraiNKondoMIzumoTTamaokiJNagaiAInhibition of neutrophil elastase-induced goblet cell metaplasia by tiotropium in miceEur Respir J20103551164117119897560
   PubMed Web of Science ®Google Scholar
• HasaniATomsNAgnewJESarnoMHarrisonAJDilworthPThe effect of inhaled tiotropium bromide on lung mucociliary clearance in patients with COPDChest200412551726173415136383
   PubMed Web of Science ®Google Scholar
• MeyerTReitmeirPBrandPEffects of formoterol and tiotropium bromide on mucus clearance in patients with COPDRespir Med2011105690090621397483
   PubMed Web of Science ®Google Scholar
• BrusascoVHodderRMiravitllesMKorduckiLTowseLKestenSHealth outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPDThorax200358539940412728159
   PubMed Web of Science ®Google Scholar
• CasaburiRMahlerDAJonesPWA long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary diseaseEur Respir J200219221722411866001
   PubMed Web of Science ®Google Scholar
• BriggsDDJrCovelliHLapidusRBhattycharyaSKestenSCassinoCImproved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPDPulm Pharmacol Ther200518639740416179215
   PubMed Web of Science ®Google Scholar
• van NoordJAAumannJLJanssensEComparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPDEur Respir J200526221422216055868
   PubMed Web of Science ®Google Scholar
• HananiaNABootaAKerwinETomlinsonLDenis-MizeKEfficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trialDrugs2009186991205121619537837
   PubMed Web of Science ®Google Scholar
• DonohueJFFogartyCLötvallJINHANCE Study InvestigatorsOnce-daily bronchodilators for chronic obstructive pulmonary disease: indaceterol versus tiotropiumAm J Respir Crit Care Med2010182215516220463178
   PubMed Web of Science ®Google Scholar
• BuhlRDunnLJDisdierCINTENSITY study investigatorsBlinded 12-week comparison of once-daily indacaterol and tiotropium in COPDEur Respir J201138479780321622587
   PubMed Web of Science ®Google Scholar
• KerwinEHébertJGallagherNEfficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 studyEur Respir J20124051106111423060624
   PubMed Web of Science ®Google Scholar
• JaraMWentworthC3rdLanesSA new user cohort study comparing the safety of long-acting inhaled bronchodilators in COPDBMJ Open201223e000841
   Web of Science ®Google Scholar
• Medicines and Healthcare Products Regulatory AgencyTiotropium. Safety studies of Spiriva Respimat2010 Available from http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON099869Accessed February 12, 2013
   Google Scholar
• WiltTJNiewoehnerDMacDonaldRKaneRLManagement of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guidelineAnn Intern Med2007147963965317975187
   PubMed Web of Science ®Google Scholar
• ObaYZazaTThameemDMSafety, tolerability and risk benefit analysis of tiotropium in COPDInt J Chron Obstruct Pulmon Dis20083457558419281075
   PubMedGoogle Scholar
• DecramerMMolenberghsGLiuDUPLIFT investigatorsRespir Med2011105101523153021530213
   PubMed Web of Science ®Google Scholar
• Breekveldt-PostmaNSKoerselmanJErkensJALammersJWHeringsRMEnhanced persistence with tiotropium compared with other respiratory drugs in COPDRespir Med200710171398140517368011
   PubMed Web of Science ®Google Scholar
• CramerJABradley-KennedyCScaleraATreatment persistence and compliance with medications for chronic obstructive pulmonary diseaseCan Respir J2007141252917315055
   PubMed Web of Science ®Google Scholar
• ShortPMWilliamsonPAElderDHLipworthSISchembriSLipworthBJThe impact of tiotropium on mortality and exacerbations when added to inhaled corticosteroids and long-acting β-agonist therapy in COPDChest20121411818621799028
   PubMed Web of Science ®Google Scholar